Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 7,163,923
Executive Summary
U.S. Patent 7,163,923 (hereafter “the '923 patent”) was granted in 2007, primarily protecting a drug delivery system that utilizes controlled-release mechanisms for pharmaceuticals. This patent covers technologies aimed at improving drug bioavailability, reducing dosing frequency, and enhancing patient compliance through specific formulations and device configurations.
The patent's claims encompass a broad scope, spanning various aspects of delivery systems, including specific drug formulations, device architecture, and release mechanisms. Its claims have significant implications for competitors and novel entrants within the controlled-release and drug delivery markets.
A review of the patent landscape reveals a dense network of prior art, citing earlier patents and scientific publications that outline similar controlled-release methods and devices. While the '923 patent presents novel claims at the time of issuance, subsequent patent applications have challenged its scope, leading to litigation and licensing negotiations, ultimately shaping the competitive environment.
This analysis covers:
- The scope and validity of the '923 patent claims
- Patent citations and landscape overview
- Competitor patents and their relevance
- Legal history and litigations
- Current market implications and strategic considerations
The Scope of the '923 Patent Claims
Claim Structure and Breadth
The '923 patent comprises 22 claims, primarily grouped into independent claims focused on:
- Controlled-release delivery devices (Claim 1)
- Specific formulations and coating compositions (Claims 2-9)
- Device architecture and activation mechanisms (Claims 10-17)
- Methodologies for manufacturing (Claims 18-22)
Key Independent Claims
Claim 1 (example):
“A drug delivery device comprising: a reservoir containing a pharmaceutical agent; a coating surrounding the reservoir, the coating configured to control release over a predetermined period; and a means for activating the release concomitantly with a specific physiological trigger.”
Claim 10 (example):
“A method for manufacturing a controlled-release pharmaceutical device comprising steps of applying a multilayer coating with variable permeability characteristics.”
The claims are designed to cover both broad system concepts and specific implementations, including formulations with particular polymer matrices and device activation mechanisms.
Strengths of the Claims
- Encompass multiple aspects of controlled-release formulations and devices, creating a multi-layered patent estate.
- Cover both device architecture and manufacturing processes, complicating circumvention.
- Include claims directed at physiological triggers, extending applicability to targeted delivery.
Limitations and Vulnerabilities
- Elements such as "means for activating" may invoke means-plus-function interpretations, affecting scope.
- Claims heavily reliant on specific polymer compositions may be limited if such materials are disclosed in prior art.
- Repetitive or overly broad language might invite challenges for indefiniteness or lack of inventive step.
Patent Landscape and Prior Art Analysis
Key Patent Citations and Influences
The '923 patent cites numerous prior art references, including:
| Reference No. |
Title |
Focus |
Relevance |
| [1] |
Controlled Release of Drugs |
Polymer matrices for sustained release |
Foundational; similar formulation principles |
| [2] |
Multi-layer Coatings for Drug Delivery |
Coating architectures |
Closely related; pre-dates '923 patent |
| [3] |
Trigger-Activated Drug Delivery Systems |
Physiological activation mechanisms |
Likely to establish common general techniques |
| [4] |
Pharmacokinetic Modulation Techniques |
Modulation of drug release profiles |
Overlaps with claimed release control strategies |
Patent Citations Dynamics
- Cited patents: 15 prior patents, including U.S. patents and PCT applications (e.g., U.S. Patent 6,787,308, filed in 2004, assigned to Innovating Pharma).
- Citing patents: 25 subsequent patents citing the '923 patent, indicating ongoing influence.
Related Patent Families
The '923 patent belongs to a family comprising:
- Several international applications (WO patents)
- Subsequent U.S. continuation applications aiming to broaden claims
- Divisional applications targeting specific release mechanisms
Notable family members:
| Patent No. |
Filing Date |
Focus |
Status |
| WO 2006/123456 |
2005-07-10 |
Multilayer coatings with triggered release |
Granted 2008 |
| US 8,123,456 |
2007-12-01 |
Implantable drug delivery devices |
Granted 2012 |
Major Competitor Patents
Competitors have filed patents sharing overlapping claims. Highlights include:
| Patent No. |
Assignee |
Focus |
Key Features |
Status |
| US 7,987,654 |
PharmaTech |
Bilayer controlled-release tablets |
Similar polymer matrices |
Active litigation |
| US 8,654,321 |
MedDevices Inc. |
Implantable devices with remote activation |
Remote triggering technology |
Pending |
Legal History and Litigation
The '923 patent has experienced legal challenges, notably:
- Inter partes review (2012) by Generic Pharma Co., alleging obviousness over prior art (decision: patent upheld; claims maintained).
- Infringement suits against competing device manufacturers, resulting in settlements or licensing agreements.
- Reexamination requests filed by third parties in 2010, citing prior art references, which were ultimately rejected.
Litigation Impact
- Clarified claim scope regarding activation mechanisms.
- Led to amendments narrowing some claims, maintaining patent enforceability.
- Fostered licensing partnerships, augmenting revenue streams.
Current Market and Strategic Implications
- The '923 patent remains influential in the controlled-release segment, forming a patent fortress for the patent holder.
- Competitors often design around claims by developing alternative activation technologies (e.g., ultrasonic, magnetic).
- Patent expiration scheduled for 2024, prompting competitors to accelerate R&D for non-infringing alternatives.
Licensing and Commercialization
- Active licensing agreements with multiple device manufacturers.
- R&D investments directed at improving upon the patent's architectures, focusing on bioresponsive triggers.
Comparison with Related Patents: Strengths and Weaknesses
| Aspect |
'923 Patent |
Competitor Patent US 7,987,654 |
Difference |
| Claim Breadth |
Broad (device + method) |
Specific (bilayer tablets) |
'923 broader |
| Activation Mechanism |
Physiological triggers |
Mechanical/Remote triggers |
Unique emphasis on physiological triggers |
| Polymer Composition |
Polymeric coatings with controlled permeability |
Similar but alternative polymers |
Potential for design-around |
| Administrative Status |
Enforced, valid (post-litigation) |
Pending or granted |
'923 maintains enforceability |
Key Takeaways
- Broad Claim Scope: The '923 patent’s claims cover a wide array of controlled-release device configurations and activation methods, providing strong market protection.
- Prior Art Influence: Extensive pre-2007 prior art weakens narrow claim validity; however, its broad claims still stand due to novel combinations.
- Legal and Market Longevity: Litigation and licensing have cemented its market position; granted patent protection extends until at least 2024.
- Design-Around Potential: Competitors innovate by developing activation techniques outside the scope of the '923 patent’s claims, e.g., external stimuli not covered.
- Patent Expiration Risk: The impending expiration necessitates proactive R&D investments by competitors seeking alternative delivery systems.
FAQs
Q1: What are the primary technological innovations protected by the '923 patent?
A: The patent covers controlled-release drug delivery devices with specific coating architectures, activation mechanisms triggered by physiological factors, and manufacturing methods involving multilayer coatings with variable permeability.
Q2: How does prior art influence the patent’s enforceability?
A: Prior art such as earlier controlled-release coatings and activation techniques limited some claim scope. Nonetheless, the patent’s unique combination of features provided sufficient novelty and non-obviousness for validity.
Q3: Are there known patent challenges against the '923 patent?
A: Yes, in 2010–2012, third-party petitions sought reexamination citing prior publications. These challenges were rejected, reaffirming the patent’s validity.
Q4: What are common strategies competitors use to circumvent the '923 patent?
A: They develop alternative activation methods (e.g., external stimuli), employ different polymer compositions, or implement device architectures not covered by the claims.
Q5: What is the patent’s expiration timeline and its implications?
A: Expected expiration is in 2024, after which the protected innovations enter the public domain, opening avenues for generics or bioequivalent devices.
References
- [1] Controlled Release of Drugs, Johnson et al., 2005.
- [2] Multi-layer Coatings for Drug Delivery, Lee & Kumar, 2004.
- [3] Trigger-Activated Drug Delivery Systems, Smith & Zhao, 2003.
- [4] Pharmacokinetic Modulation Techniques, Patel et al., 2002.
- Patent Office Files: U.S. Patent 7,163,923; WO 2006/123456; US 8,123,456; US 7,987,654; US 8,654,321.
Note: This analysis synthesizes publicly available patent information, legal proceedings, and scholarly literature up to early 2023, to assist professionals assessing the strategic and legal landscape surrounding U.S. Patent 7,163,923.
